The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Mon., Jan. 24, 2:20 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #37. AstraZeneca Diabetes Alliance Assets in the U.S. from Bristol-Myers Squibb

Acquirer: AstraZeneca (NASDAQ:AZN)
Acquiree: Diabetes Alliance Assets in the U.S. from Bristol-Myers Squibb
Details: AstraZeneca (NYSE:AZN) today announced that on February 1, 2014, it completed its acquisition of the entirety of Bristol-Myers Squibb's interests in the companies' diabetes alliance. The acquisition gives AstraZeneca ownership of the intellectual property and global rights for the development, manufacture and commercialization of the diabetes business, which in the U.S. includes ONGLYZA (saxagliptin), KOMBIGLYZE XR (saxagliptin and metformin HCl extended release), FARXIGA (dapagliflozin), BYETTA (exenatide), BYDUREON (exenatide extended-release for injectable suspension), Symlin (pramlintide acetate) and the investigational agent metreleptin.

AstraZeneca is a holding company. Through its subsidiaries, Co. is engaged in biopharmaceutical business. Co. focuses on three main therapy areas: oncology - aims to change the practice of medicine and transform the lives of patients living with cancer; cardiovascular, renal & metabolism includes treatment of four interrelated conditions - cardiovascular disease, heart failure, metabolic and renal diseases; and respiratory and immunology - aims to transform the treatment of asthma and COPD by eliminating preventable asthma attacks across disease severities and removing COPD as a cause of death through earlier, biology-led treatment.

Open the AZN Page at The Online Investor »

Company Name: 
AstraZeneca Plc
Drugs & Pharmaceuticals
Number of ETFs Holding AZN: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the AZN Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree AZN Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (3.43 out of 4)
41st percentile
(ranked lower than approx. 59% of all stocks covered)

Analysts' Target Price:
AZN Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 37 of 100 Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.